GlaxoSmithKline (GSK) has presented new results from a late-stage clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in people 50 years of age or older, Shingrix, induces a strong immune response in older adults who have been vaccinated against shingles with the currently available live-attenuated zoster (ZVL)

A review published in Clinical Chemistry has identified 10 genes that show promise in predicting how patients will respond to opioid pain medications. Using these genetic markers, health care providers could potentially tailor opioid therapy better to curb the skyrocketing rate of deaths from these drugs, the authors claim.

When Senate Republicans unveil their plan to overhaul the Patient Protection and Affordable Care Act (PPACA), they will face a skeptical public that already doesn’t buy the justification for an earlier version that passed the House of Representatives, according to a new Reuters/Ipsos survey.

Approximately half a million clinicians who participated in the Centers for Medicare and Medicaid Services’ (CMS) Physician Quality Reporting System (PQRS) will be hit with a 2% Medicare penalty this year because they didn’t meet program requirements, according to a report from FierceHealthcare.

A seven-year push by Republicans to dismantle the Patient Protection and Affordable Care Act (PPACA) has finally reached a critical phase as Senate GOP leaders unveiled a draft bill that they aim to put to a vote, possibly as early as next week, according to a Reuters report.

Residents in Wisconsin and Indiana who buy insurance on the ACA exchanges will have fewer options next year as Anthem announced yesterday that it is pulling out of those states, the New York Times reports.

The situation is fluid, as it has been since the GOP took over the Senate in January partly because of a promise to repeal and replace Obamacare.

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has completed its meeting regarding a supplemental new drug application (sNDA) for the inclusion of data from a pivotal cardiovascular outcomes trial in the labeling for liraglutide (Victoza, Novo Nordisk) injection.

The FDA has given the nod to Mydayis (mixed salts of a single-entity amphetamine product, Shire), a once-daily treatment consisting of three different types of drug-releasing beads for patients 13 years of age and older with attention-deficit/hyperactivity disorder (ADHD). Mydayis is not intended for use in children 12 years of age and younger.

At St. Joseph Hospital in Orange, California, nurse Dawn Nagel is the last line of defense against sepsis, according to an article from Kaiser Health News. Her mission: identify and treat sepsis patients quickly to minimize their risk of death.

The Centers for Medicare and Medicaid Services (CMS) has issued a proposed rule that would make changes in the second year of the Quality Payment Program, as required by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

FDA Commissioner Scott Gottlieb, MD, has announced in a blog post that the agency plans to hold a public meeting on July 18 to identify ways pharmaceutical companies are using FDA rules—including the standards and procedures related to generic drug approvals—to place obstacles in the way of generic competition.

The Trump administration believes that reining in regulations on pharmaceutical companies is the best way to control the cost of drugs, the New York Times reports.

Major insurers have announced that they’ll not participate in the Obamacare market exchanges next year, and time’s running out for those health plans still on the fence since they must file their intentions and proposed premium rates today.

The FDA has approved delafloxacin (Baxdela, Melinta Therapeutics) for the treatment of adults with acute bacterial skin and skin-structure infections (ABSSSI) caused by susceptible bacteria.